PE20142242A1 - Anticuerpos humanos anti-cd27, metodos, y usos - Google Patents
Anticuerpos humanos anti-cd27, metodos, y usosInfo
- Publication number
- PE20142242A1 PE20142242A1 PE2014001420A PE2014001420A PE20142242A1 PE 20142242 A1 PE20142242 A1 PE 20142242A1 PE 2014001420 A PE2014001420 A PE 2014001420A PE 2014001420 A PE2014001420 A PE 2014001420A PE 20142242 A1 PE20142242 A1 PE 20142242A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- group
- methods
- activity
- human antibodies
- Prior art date
Links
- 102100027207 CD27 antigen Human genes 0.000 abstract 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO HUMANO AISLADO CD27 QUE COMPRENDE UNA REGION VARIABLE DE CADENA LIVIANA; QUE CONTIENE: A) UNA SECUENCIA DE AMINOACIDOS DE LA REGION DETERMINANTE DE COMPLEMENTARIEDAD DE CADENA LIGERA 1 ( CDRL1) SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID N� 59-66 Y 158, CDRL2 SELECCIONADO DEL GRUPO QUE CONSISTE EN SEQ ID N� 67-74, CDRL3 SELECCIONADO DEL GRUPO QUE CONSISTE EN SEQ ID N� 75; Y B) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE: CDRH1 SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID N�42-45 Y 161, CDRH2 SELECCIONADO DEL GRUPO QUE CONSISTE EN 46-57, 156 Y 157, CDRH3 DE SEQ ID N� 58. DICHOS ANTICUERPOS SON UTILES PARA DIAGNOSTICAR O TRATAR LA ACTIVIDAD DE ENFERMEDADES Y ESTADOS ASOCIADOS CON LA ACTIVIDAD DE CD27.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611332P | 2012-03-15 | 2012-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142242A1 true PE20142242A1 (es) | 2015-01-08 |
Family
ID=49157853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001420A PE20142242A1 (es) | 2012-03-15 | 2013-03-14 | Anticuerpos humanos anti-cd27, metodos, y usos |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US9102737B2 (es) |
| EP (1) | EP2825200A4 (es) |
| JP (1) | JP6487839B2 (es) |
| KR (1) | KR102153374B1 (es) |
| CN (1) | CN104284678B (es) |
| AR (1) | AR090356A1 (es) |
| AU (1) | AU2013232087B2 (es) |
| BR (2) | BR122020002414B1 (es) |
| CA (1) | CA2867299C (es) |
| CL (1) | CL2014002416A1 (es) |
| CO (1) | CO7071095A2 (es) |
| CR (1) | CR20140415A (es) |
| EA (1) | EA030828B1 (es) |
| EC (1) | ECSP14018641A (es) |
| GT (1) | GT201400193A (es) |
| HK (1) | HK1206251A1 (es) |
| JO (1) | JO3787B1 (es) |
| MX (1) | MX363946B (es) |
| MY (1) | MY175224A (es) |
| NZ (1) | NZ629697A (es) |
| PE (1) | PE20142242A1 (es) |
| PH (2) | PH12014502011B1 (es) |
| SG (2) | SG10201710574UA (es) |
| TW (2) | TW201730214A (es) |
| UA (1) | UA121844C2 (es) |
| UY (1) | UY34680A (es) |
| WO (1) | WO2013138586A1 (es) |
| ZA (2) | ZA201407440B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101958753B1 (ko) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 ｃｄ27에 결합하는 항체 및 이의 용도 |
| CA2828753C (en) | 2011-03-16 | 2022-07-26 | arGEN-X BV | Antibodies to cd70 |
| WO2014140374A2 (en) * | 2013-03-15 | 2014-09-18 | Novo Nordisk A/S | Monovalent cd27 antibodies |
| TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| FR3025517B1 (fr) | 2014-09-10 | 2016-12-23 | Repropharm | Ligands potentialisants de la bioactivite des gonadotrophines |
| WO2017044752A1 (en) * | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
| MX2018003905A (es) | 2015-09-30 | 2018-09-06 | Janssen Biotech Inc | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso. |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| CN108430492B (zh) * | 2015-10-23 | 2022-05-03 | 阿珀吉科吉尼科斯股份公司 | 单链cd27受体激动剂蛋白 |
| US20170233480A1 (en) | 2015-12-31 | 2017-08-17 | Development Center For Biotechnology | Anti-vegfr antibody and uses thereof |
| EP3445783A2 (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| JOP20190055A1 (ar) * | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| TW201813979A (zh) * | 2016-09-29 | 2018-04-16 | 江蘇恆瑞醫藥股份有限公司 | 抗ｃｄ２７抗體、其抗原結合片段及其醫藥用途 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP4653464A2 (en) * | 2016-12-23 | 2025-11-26 | MacroGenics, Inc. | Adam9-binding molecules, and methods of use thereof |
| MY201573A (en) | 2017-05-12 | 2024-03-02 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| EP3648757A4 (en) * | 2017-07-03 | 2020-11-25 | Development Center for Biotechnology | ANTI-VEGFR ANTIBODIES AND ITS USES |
| WO2019037131A1 (zh) * | 2017-08-25 | 2019-02-28 | 深圳市博奥康生物科技有限公司 | 一种cd27真核表达载体的构建及其高表达细胞株的制备 |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| JP7359390B2 (ja) * | 2018-02-09 | 2023-10-11 | 国立大学法人大阪大学 | チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途 |
| MX2020010119A (es) * | 2018-03-28 | 2020-10-15 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. |
| JP7680208B2 (ja) * | 2018-04-04 | 2025-05-20 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｃｄ２７抗体およびその使用 |
| US11795230B2 (en) | 2018-04-13 | 2023-10-24 | Dingfu Biotarget Co., Ltd. | Anti-CD27 antibodies and use thereof |
| MX2020010913A (es) | 2018-04-17 | 2021-01-08 | Celldex Therapeutics Inc | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. |
| JP7542441B2 (ja) | 2018-05-11 | 2024-08-30 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 癌を治療するための方法及び組成物 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| US20220016168A1 (en) | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| TWI848030B (zh) | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| US20220144961A1 (en) * | 2019-03-11 | 2022-05-12 | Xyence Therapeutics, Inc. | Cd27-binding antibodies and uses thereof |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| TW202112812A (zh) * | 2019-05-24 | 2021-04-01 | 香港商安立璽榮生醫(香港)有限公司 | Csf1r抗體、il10融合蛋白及其用途 |
| JOP20220049A1 (ar) * | 2019-08-30 | 2023-01-30 | Janssen Biotech Inc | مشرعات وتركيبات car t خاصة بمركب نضج الخلايا البائية |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| TW202208427A (zh) * | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗ｃ５ａ抗體 |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CN112646029B (zh) * | 2020-12-30 | 2022-07-29 | 深圳清华大学研究院 | 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒 |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| CN116120451A (zh) * | 2021-06-17 | 2023-05-16 | 南京蓝盾生物科技有限公司 | 抗cd70内化的抗体、抗体偶联物及其应用 |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| CN116262788A (zh) * | 2021-12-15 | 2023-06-16 | 泰泽惠康生物医药有限责任公司 | 抗cd27抗体分子 |
| JP2025509832A (ja) | 2022-03-15 | 2025-04-11 | コンピュジェン リミテッド | Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用 |
| CN115165829B (zh) * | 2022-06-29 | 2025-07-29 | 上海交通大学 | 一种定量分析系统性红斑狼疮免疫细胞与功能蛋白的方法及其应用 |
| WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN118667002A (zh) * | 2023-03-16 | 2024-09-20 | 上海赛金生物医药有限公司 | 抗cd27单克隆抗体及其应用 |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| CN119661718B (zh) * | 2025-02-20 | 2025-06-06 | 杭州华大生命科学研究院 | 一种抗cd27纳米抗体及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218525B1 (en) | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| US6982361B1 (en) | 2000-02-25 | 2006-01-03 | The Regents Of The University Of California | Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| JP2005512962A (ja) | 2001-09-20 | 2005-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｐｄｇｆ抗体および設計抗体の産生方法 |
| AU2003210266A1 (en) | 2002-02-14 | 2003-09-04 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
| US20060228710A1 (en) | 2003-02-14 | 2006-10-12 | Morris David W | Novel therapeutic targets in cancer |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| US20110129412A1 (en) | 2005-06-02 | 2011-06-02 | Astrazeneca Ab | Antibodies Directed to CD20 and Uses Thereof |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos |
| EP2090320A1 (en) * | 2008-02-15 | 2009-08-19 | Helmholtz-Zentrum für Infektionsforschung GmbH | Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof |
| CA2729567C (en) * | 2008-06-30 | 2018-04-24 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd27 antibody |
| WO2010080463A1 (en) * | 2008-12-18 | 2010-07-15 | Imclone Llc | Antibody humanization |
| EP2520589B1 (en) * | 2009-12-29 | 2018-11-07 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd27 antibody |
| KR101958753B1 (ko) * | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 ｃｄ27에 결합하는 항체 및 이의 용도 |
| CA2804550C (en) * | 2010-07-09 | 2021-01-05 | Bionovion Holding B.V. | Agonistic antibody to cd27 |
-
2013
- 2013-03-14 PE PE2014001420A patent/PE20142242A1/es active IP Right Grant
- 2013-03-14 MY MYPI2014702561A patent/MY175224A/en unknown
- 2013-03-14 HK HK15106811.7A patent/HK1206251A1/xx unknown
- 2013-03-14 KR KR1020147028682A patent/KR102153374B1/ko active Active
- 2013-03-14 AU AU2013232087A patent/AU2013232087B2/en active Active
- 2013-03-14 NZ NZ629697A patent/NZ629697A/en unknown
- 2013-03-14 CA CA2867299A patent/CA2867299C/en active Active
- 2013-03-14 WO PCT/US2013/031314 patent/WO2013138586A1/en not_active Ceased
- 2013-03-14 CN CN201380025446.3A patent/CN104284678B/zh active Active
- 2013-03-14 SG SG10201710574UA patent/SG10201710574UA/en unknown
- 2013-03-14 BR BR122020002414-3A patent/BR122020002414B1/pt active IP Right Grant
- 2013-03-14 BR BR112014022812A patent/BR112014022812A2/pt not_active Application Discontinuation
- 2013-03-14 SG SG11201405437QA patent/SG11201405437QA/en unknown
- 2013-03-14 JP JP2015500608A patent/JP6487839B2/ja active Active
- 2013-03-14 JO JOP/2013/0072A patent/JO3787B1/ar active
- 2013-03-14 EA EA201491700A patent/EA030828B1/ru unknown
- 2013-03-14 UA UAA201411147A patent/UA121844C2/uk unknown
- 2013-03-14 MX MX2014011100A patent/MX363946B/es active IP Right Grant
- 2013-03-14 EP EP13761537.3A patent/EP2825200A4/en active Pending
- 2013-03-15 AR ARP130100851A patent/AR090356A1/es active IP Right Grant
- 2013-03-15 UY UY0001034680A patent/UY34680A/es not_active Application Discontinuation
- 2013-03-15 TW TW106102009A patent/TW201730214A/zh unknown
- 2013-03-15 TW TW102109158A patent/TWI576354B/zh active
- 2013-03-15 US US13/835,518 patent/US9102737B2/en active Active
-
2014
- 2014-09-09 CR CR20140415A patent/CR20140415A/es unknown
- 2014-09-09 PH PH12014502011A patent/PH12014502011B1/en unknown
- 2014-09-12 CO CO14202427A patent/CO7071095A2/es unknown
- 2014-09-12 CL CL2014002416A patent/CL2014002416A1/es unknown
- 2014-09-12 EC ECIEPI201418641A patent/ECSP14018641A/es unknown
- 2014-09-12 GT GT201400193A patent/GT201400193A/es unknown
- 2014-10-14 ZA ZA2014/07440A patent/ZA201407440B/en unknown
-
2015
- 2015-02-06 ZA ZA2015/00887A patent/ZA201500887B/en unknown
- 2015-07-02 US US14/790,144 patent/US9683046B2/en active Active
-
2017
- 2017-05-16 US US15/596,609 patent/US10301392B2/en active Active
- 2017-10-19 PH PH12017501908A patent/PH12017501908B1/en unknown
-
2019
- 2019-04-12 US US16/382,645 patent/US10689453B2/en active Active
-
2020
- 2020-05-19 US US16/878,209 patent/US11732050B2/en active Active
-
2023
- 2023-06-29 US US18/216,074 patent/US20240141055A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| NZ744185A (en) | Antibodies and conjugates thereof | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| AR081556A1 (es) | Proteinas de union al antigeno humanizadas | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| JP2020500538A5 (es) | ||
| AR086579A1 (es) | Proteinas de union a antigeno | |
| EP4538372A3 (en) | Anti-trop2 antibody | |
| NZ610153A (en) | Novel anti-dr5 antibody | |
| PE20171244A1 (es) | Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmunorreceptor (tigit) | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| WO2012045481A3 (en) | Antibody targeting osteoclast-related protein siglec-15 | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| NZ605980A (en) | Anti-fap antibodies and methods of use | |
| AR087405A1 (es) | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| NZ603488A (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| NZ596274A (en) | Blocking anti-dkk-1 antibodies and their uses | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |